Empagliflozin 12.5 MG + Metformin Hcl 1000 MG Tablets- Xempia M 12.5/1000 Tablets

Empagliflozin 12.5 MG + Metformin Hcl 1000 MG Tablets – An effective and comprehensive approach to managing T2DM.

Xempia M 12.5/1000 – Empagliflozin 12.5 mg + Metformin HCL 1000 mg, this combination tablet is designed to provide comprehensive control over Type 2 Diabetes by leveraging the complementary actions of Empagliflozin and Metformin.
✅Empagliflozin: A sodium-glucose cotransporter-2 (SGLT2) inhibitor that helps lower blood sugar by preventing glucose reabsorption in the kidneys. It also promotes weight loss and provides cardiovascular protection.
✅Metformin: A biguanide, works by decreasing the glucose production in the liver, improving insulin sensitivity, and enhancing peripheral glucose uptake.
Together, these agents offer powerful glycemic control and additional health benefits for diabetic patients.

Recommended by specialists:
✅Diabetologists – To comprehensively manage Type 2 Diabetes Mellitus (T2DM), ensuring better glycemic control.
✅Cardiologists – To help reduce cardiovascular risk in diabetic patients, particularly those at risk of heart failure or with existing heart conditions.
✅Nephrologists – To support kidney health by slowing the progression of diabetic nephropathy and reducing the risk of kidney complications.

Key benefits of Empagliflozin 12.5 MG + Metformin Hcl 1000 MG – Xempia M 12.5/500 Tablets:
✅Dual Action Formula: Combines the blood sugar-lowering effects of Empagliflozin, an SGLT2 inhibitor, with Metformin, a well-known biguanide, for superior glycemic control.
✅Weight and Cardiovascular Benefits: Empagliflozin helps with weight management and provides cardiovascular benefits, reducing the risk of heart-related events in diabetic patients.
✅Convenient Dosage: Offers a once-daily, dual-action approach to managing Type 2 Diabetes, improving patient adherence and simplifying treatment.

Indications –
✅Type 2 Diabetes Mellitus
✅To improve glycemic control in patients with inadequate blood sugar control
✅Cardiovascular risk reduction in patients with Type 2 Diabetes